-
For Health Care Professionals: Preventing Thrombosis in COVID-19 –Anticoagulation Algorithm
Stephan Moll, MD writes (last updated: Sept 9th, 2020)… Background: Hospitalized patients with COVID-19 are at increased risk for thrombosis – DVT, PE, and may be pulmonary micro-vascular thrombosis that possibly contributes to respiratory failure; arterial events appear to occur less commonly. Scientific/clinical data on prevalence of thrombosis, best prevention, and optimal therapy are limited.…
-
Pradaxa – What Your Physician/Hospital Wants to Know
If you are considering to start therapy with the new oral “blood thinner” Pradaxa®, there are a few safety nets that your local hospital and physician may want to establish to make therapy as safe as possible for you. Issues to be addressed are (a) dosing, (b) management of major bleeding, (c) interruption of therapy…
-
Pradaxa (Dabigatran) – Hospital Guideline
The new oral anticoagulant Pradaxa® (Dabigatran) is increasingly being used as an alternative to warfarin. A number of practical management questions are now encountered by the physician, pharmacist, or other health care professional taking care of the patient on Pradaxa®, such as (a) dosing in renal impairment, (b) conversion of a patient on warfarin…
A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center
Clot Connect 